Business Wire

Aqara Adds Presence Sensor FP2 to its Smart Sensor Portfolio

20.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a leading provider of smart home products, expands its wide-ranged smart sensor portfolio with the introduction of the Presence Sensor FP2, a revolutionary sensor for precise human presence detection. Equipped with the millimeter wave (mmWave) radar technology, the FP2 solves many pain points of the traditional passive infrared (PIR) presence sensors and enables a more tailored and rich smart home experience. The new sensor is now available on the Company’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as selective Aqara retailers worldwide1.

Accurate human presence detection provides essential information for tailored smart home automations such as home security monitoring and energy management systems (e.g., automated lights, HVAC, home appliances control). The mmWave-based FP2 Presence Sensor takes a leap forward from the PIR motion sensors as the former detects a person’s presence with even the slightest movement such as the act of breathing. Gone are the frustrating experiences of having your smart lights turn off unintentionally because you were sitting still reading a book or working at the desk.

Moreover, the FP2 sensor raises the precision of human detection to the next level with its capability to monitor multiple zones and multiple targets simultaneously. The FP2 allows the user to define up to 30 zones within a room (up to 40 sq m/430 sq ft). For example, the living room and dining area can be configured as separate zones with individualized automations. This sensor tracks up to 5 persons at the same time2, making it possible to control different zones based on the real-time location of each family member. For instance, to dim the dining area lights and switch the TV on when the kids leave the dining table and move to the sofa, meanwhile to keep the kitchen light on when someone is washing the dishes.

The powerful capabilities of the FP2 sensor can also be used within the third-party smart home platforms including Apple Home, Amazon Alexa, Google Home, Home Assistant3 and more. Once the zones are set up in the Aqara Home app, the zone configuration can be synced to these platforms as multiple motion/occupancy sensors, allowing users to trigger zone-based automation with a wide variety of third-party smart home devices. Support of the new smart home standard, Matter, is also planned for the FP2, and will be added to the device via a subsequent OTA update4.

Aside from its precise presence detection and multi-zone automations, FP2 also has fall detection built-in5, which is particularly essential for senior citizens who are more vulnerable to fall injuries. Families and caregivers can be alerted by both local siren and remote alerts if the FP2 sensor detects a fall, which allows them to seek immediate assistance if necessary. The FP2 sensor can detect a fall at the home in a convenient way without the need to wear additional devices on the body. At the same time, unlike a typical security camera, the Sensor provides meaningful alerts and data without intruding on a person’s personal privacy.

Thanks to its powerful hardware, the FP2 sensor will be able to support much more cutting-edge features in the future such as posture detection, which not only recognizes falls but also other postures including standing, sitting, and lying. Sleep monitoring and respiratory rate detection capabilities could also be achieved via the FP2 in the future. These advanced features will be added to the FP2 sensor via future OTA updates4.

For more details of the Presence Sensor FP2, please visit our website.

  1. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real-time availability.
  2. The best result can be achieved in the case of tracking not more than 3 persons.
  3. The FP2 sensor can be added to Home Assistant using HomeKit Controller integration.
  4. Some features of the FP2 sensor such as Matter support, posture detection and sleep monitor are not available by the time of launch.
  5. The Presence Sensor FP2 is not a medical device, and can only be used for notification purposes. Ceiling-mounted installation is required for fall detection, and the monitoring area will decrease when the FP2 is ceiling-mounted. In fall detection mode, many functionalities of the FP2 become unavailable, including zone positioning and multi-person detection.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Inquiry:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye